Binx Health IO CT/NG Assay: The World's First 30-Minute Molecular Point-of-Care Test for Chlamydia and Gonorrhea

Abstract

The binx io Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Assay running on the binx io platform is designed to reduce the time taken between testing for CT and NG and treating appropriately from days and weeks to minutes – enabling a ‘test and treat’ approach for the first time. The io was recently cleared by the FDA for use in point-of-care or clinical laboratory settings for the detection of CT and NG in female vaginal swab samples following a validation study that demonstrated a 96.1% sensitivity and 99.1% specificity for CT and 100% sensitivity and 99.9% specificity for NG.